ERBB2 and breast carcinoma: In breast cancer, the study of gene expression alterations and their relation to clinical outcomes is the most mature, whereas DNA copy number aberrations and clinical course has not advanced as far (with one notable exception, HER2), and much less is understood about somatic mutations and therapy response and survival.